{"entity":{"id":"b7h3","kind":"target","name":"B7-H3","aka":[],"tldr":"B7-H3 is an immune checkpoint-like surface protein found on 60 to 70% of small-cell lung cancers and 80 to 90% of castration-resistant prostate cancers, with little on normal tissue. It is used as an ADC address, chiefly by ifinatamab deruxtecan, now in phase 3 in small-cell lung cancer; whether blocking its immune-dampening role adds anything beyond payload delivery is unresolved.","summary":"B7-H3 (CD276) is an immune checkpoint-like molecule broadly overexpressed in solid tumours with limited normal expression; its function is debated, inhibiting T-cell activation and promoting tumour cell migration. Expression is more homogeneous than many ADC targets, found in 60-70% of small-cell lung cancer and 80-90% of castration-resistant prostate cancer by IHC, as well as head and neck and paediatric solid tumours. Ifinatamab deruxtecan (I-DXd) has shown high response rates in small-cell lung cancer and is in phase 3. B7-H3 is also pursued with radioligands and CAR-T. Whether its immune-dampening role means antibodies against it add an immunological benefit beyond payload delivery is unresolved. The simple version is a widely present tumour surface protein now used mainly as an address for ADCs.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/CD276","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/CD276"}],"tags":["adc-target"],"related":[],"indications":["sclc","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"CD276","hgnc":"HGNC:19137","ensembl":"ENSG00000103855","uniprot":"Q5ZPR3","entrez":"80381","biology":"Function debated: inhibits T-cell activation, promotes tumour cell migration. Expression is more homogeneous than many ADC targets.","whereFound":["Small-cell lung cancer","Prostate","Head and neck","Paediatric solid tumours"],"targetClass":"surface-antigen","prevalence":[{"indicationId":"sclc","pct":"60-70","measure":"IHC, any expression","source":"https://en.wikipedia.org/wiki/CD276"},{"indicationId":"prostate","pct":"80-90","measure":"IHC, any expression","source":"https://en.wikipedia.org/wiki/CD276","note":"Castration-resistant disease"}]},"route":"/targets/b7h3/","neighbours":{"indication":[{"id":"glioblastoma","kind":"indication","name":"Glioma & glioblastoma","route":"/indications/glioblastoma/"},{"id":"osteosarcoma","kind":"indication","name":"Osteosarcoma","route":"/indications/osteosarcoma/"},{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"},{"id":"sclc","kind":"indication","name":"Small-cell lung cancer","route":"/indications/sclc/"}],"company":[{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","route":"/companies/aktis-oncology/"}],"pathway":[{"id":"lineage-plasticity-neuroendocrine","kind":"pathway","name":"Lineage plasticity & neuroendocrine transformation","route":"/pathways/lineage-plasticity-neuroendocrine/"}],"idea":[{"id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/"}],"technology":[{"id":"pretargeted-radioimmunotherapy","kind":"technology","name":"Pretargeted radioimmunotherapy","route":"/technologies/pretargeted-radioimmunotherapy/"}]}}